Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update

Pasithea Therapeutics Corp. (NASDAQ:KTTA) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 26,700 shares, an increase of 641.7% from the January 31st total of 3,600 shares. Currently, 2.6% of the company’s shares are sold short. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 0.0 days.

Pasithea Therapeutics Stock Performance

NASDAQ:KTTA traded down $0.06 during midday trading on Friday, hitting $1.16. 50,586 shares of the company traded hands, compared to its average volume of 530,773. The firm’s fifty day moving average is $2.22 and its 200-day moving average is $3.36. Pasithea Therapeutics has a 12-month low of $1.12 and a 12-month high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.